Intravenous infusion of cord blood cells (CBC) in patients with Parkinson disease
V.N. Smirnov
Department of Neurology, N.Burdenko Main Military Hospital,,Moscow, Russia
Abstract:
Investigation was pilot study to estimate the safety and effectiveness of single intravenous infusion of allogeneic ABO/Rh+identical, RBC-depleated human CBC at average dose of 250 ? 106 cells to patients with Parkinson disease. Eight patients with stable neurological deficit on standard therapy were included in the study. Clinical state of patients was estimated in 2 weeks and 1,3,6 months after cell infusion using Columbian Rating Scale (CRS) and PDQ-39 Scoring System. Clinical effects became evident during first month following infusion and continued up to 4 months, though statistically significant results were observed only for one month interval (CRS p=0.012; reduction of tremor p=0.028; reduction of rigidity p=0.018; reduction of bradykinesia p=0.043). By 2-3th months after infusion for majority of patients it was possible to decrease the dose of standard therapy by 20-40%. CBC infusions did not cause any side effects. Further investigation is warranted related to possible reiteration of infusions each 3-4 months.
